Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD

Barbara Burtness MD

Anthony N. Brady Professor of Medicine; Chief Translational Research Officer; Associate Director, Translational Science; Chief, Head and Neck Cancers/Sarcoma; Co-Leader, Developmental Therapeutics Program; Director, Yale Head and Neck SPORE, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut

Dr. Barbara Burtness is Anthony N. Brady Professor of Medicine at the Yale University School of Medicine. She is founding director of the Yale Head and Neck SPORE, co-leader of the Developmental Therapeutics Program, and director of the Head and Neck Clinical Research Program at Yale Cancer Center.

Dr. Burtness’s research focuses on clinical trials of immunotherapy and translational studies of resistance to immunotherapy and EGFR inhibition, and synthetic lethal approaches for HPV-negative head and neck cancer. She chairs the ECOG-ACRIN Head and Neck Cancer Therapeutics Committee, which conducts multicenter trials of novel treatment paradigms to improve the survival and functional outcomes of patients with all stages of head and neck cancers, and she co-leads the Stand Up to Cancer Head and Neck Cancer Team.

Dr. Burtness co-edits the text Molecular Determinants of Head and Neck Cancer. Her research has been published in numerous peer-reviewed journals, including The Lancet, Journal of Clinical Oncology, The Lancet Oncology, and Clinical Cancer Research.

Disclosures

  • Honoraria/Consulting/Data Safety Monitoring Boards: AbbVie, ALX Oncology, Astra Zeneca, Coherus, Cue Biopharma, Eisai, Glaxo Smith Kline, IMS Consulting, IO Biotech, Kura, Merck KgaA, Merck, Merus, Orphagen, Vaccinex, Slingshot Bio, Surface

Recent Contributions to PracticeUpdate:

  1. 2022 Top Story in Oncology: Nivolumab/Ipilimumab in First-Line for Recurrent/Metastatic HNSCC—CheckMate 651
  2. Overall Survival After 5 Years in Patients With Locally Advanced SCCHN Treated With Xevinapant Plus Chemoradiotherapy vs Placebo Plus CRT
  3. Phase III KEYNOTE-412: Pembrolizumab With Chemoradiation Therapy vs Placebo Plus CRT for Locally Advanced HNSCC
  4. Phase VI KEYNOTE-B10: Pembrolizumab Plus Carboplatin Plus Paclitaxel as First-line Therapy in R/M HNSCC
  5. ESMO 2022: Recommendations From Dr. Barbara Burtness for Head and Neck Cancer
  6. Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer Unsuitable for Cisplatin-Based Chemoradiation
  7. Weekly vs Three Weekly Cisplatin and Radical Radiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma
  8. Pembrolizumab and Cabozantinib for Recurrent Metastatic Head and Neck Squamous Cell Carcinoma
  9. Transoral Surgery Followed by Pathology-Based Adjuvant Treatment in HPV-Associated Oropharynx Cancer
  10. ASCO 2022: Abstract Recommendations From Dr. Barbara Burtness for Head and Neck Cancer

Most Read This Week

Recently Updated